Information Provided By:
Fly News Breaks for January 13, 2020
CHMA
Jan 13, 2020 | 19:00 EDT
Piper Sandler analyst Edward Tenthoff maintained an Overweight rating on Chiasma and increased his price target on the shares to $13 from $11 after the company announced that the FDA accepted the new drug application for Mycapssa with a June 26 PDUFA date. Tenthoff said he is "confident" in Mycapssa approval as the first oral therapy to treat acromegaly. The analyst added that the company plans to market Mycapssa in the U.S. and he now forecasts $7m in 2020 growing to $30.6M in 2021.
News For CHMA From the Last 2 Days
There are no results for your query CHMA